{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078617","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.353632+00:00","generated_at":"2026-05-17T13:26:20.330827+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Century Therapeutics Q2 net loss $32.5M; cash runway into Q4 2027; CEO named Board Chair","bullets":["Net loss of $32.5M for Q2 2025 (vs. $31.2M in Q2 2024); cash & equivalents $158.5M as of June 30.","Cash runway extended into Q4 2027 after workforce reduction completed July 2025.","CEO Brent Pfeiffenberger appointed Board Chair; Joseph Jimenez steps down, becomes special advisor.","CNTY-101 CALiPSO-1 trial dosing two patients; clinical data expected by year-end 2025.","CNTY-308 enters IND-enabling studies; clinical start planned in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078617","json":"https://secwatch.observer/filing/0001104659-25-078617.json","markdown":"https://secwatch.observer/filing/0001104659-25-078617.md","text":"https://secwatch.observer/filing/0001104659-25-078617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/0001104659-25-078617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/tm2523439d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:26:20.330827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}